FDA Clears Golimumab Biosimilars - Quiz - MDSpire

FDA Clears Golimumab Biosimilars

New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.

  • By

  • Kathryn Wighton

  • May 18, 2026

  • 2 min

Share

Original Source(s)

FDA Clears Golimumab Biosimilars

  • by Kathryn Wighton

  • May 18, 2026

Related Content

Depressive symptoms and risk of incident activities of daily living disability among older adults with symptomatic arthritis

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

RA Outcomes Improved in KURAMA Cohort

Ten-year observational data showed lower disease activity and functional disability coinciding with broader use of biologic and targeted synthetic therapies.